register

News & Trends - Biotechnology

UQ awarded Industry’s Choice Award by AusBiotech and J&J

Health Industry Hub | November 2, 2020 |

Biotech News: The University of Queensland (UQ) has been awarded the Industry’s Choice Award, the final AusBiotech and Johnson & Johnson Innovation Industry Excellence Award for 2020. The prestigious Industry Excellence Awards were announced at the AusBiotech + Invest 2020 national conference, during the biggest week in biotech.

The AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards recognise and celebrate life science leaders who are championing the sector and the Australian community through the worst pandemic and greatest collaboration seen in the sector.

The Awards celebrate those who have played a critical role guiding and inspiring us locally, and shining a light on Australia globally as a leader in the response to COVID-19. Behind these critical and timely responses are people and companies that inspire their workforce, their State, and their nation.

  • Industry’s Choice Award: University of Queensland
  • COVID-19 Life Science Sector Innovation Award: Ellume
  • Dual COVID-19 Life Science Sector Collaboration Award: University of Queensland; the Medicines Manufacturing Innovation Centre.
  • Dual COVID-19 Communication Leaders Award: Dr Rob Grenfell, Health and Biosecurity Director, CSIRO; Professor Sharon Lewin AO, Director, Doherty Institute

University of Queensland
The University of Queensland (UQ) sits at the centre of dozens of global collaborations and enabling agreements, mobilising quickly in their fight against COVID-19. Its partnering response across academic and industry partners – aided by Uniquest – includes CEPI, CSL, Doherty Institute, WHO Collaborating Centre, ANU, CSIRO, Hong Kong University, TetraQ, Patheon, Cytiva, Sypharma, Nucleus Network, GSK, Dynavax, Lonza, Life Technologies, Viroclinics Xplore, Syneos and Berkeley Lights. It has also been working closely with Federal and Queensland governments, philanthropists and donors. These partnerships aim to rapidly translate and develop the COVID-19 vaccine candidate.

Researchers have worked tirelessly to take the vaccine successfully through Phase 1 trials and into CSL’s preparation for Phase 2B/3 trials planned for December 2020. Research, clinical, and product development work that would normally take years has been accelerated into weeks and months, and planning that would typically take place sequentially is occurring simultaneously. This Australian and international research collaboration has already been extraordinary, and has the potential to be world changing.

AusBiotech + Invest 2020 conference - Health Industry Hub

An additional collaboration involving QUT, WEHI and UQ used a first-in-Australia approach to identify a genetic signature specific to patients with severe COVID-19, where excessive inflammation in the lungs can be deadly. While validation is required, this is likely to represent a prognostic signature to identify those most at risk among seriously ill patients – potentially saving lives.

Details of the other award winners are listed here.

Health Industry Hub is a proud media partner of AusBiotech + Invest 2020 national conference.


News & Trends - MedTech & Diagnostics

Sussan Ley breaks ground as first female opposition leader amid Liberal party shake-up

Sussan Ley breaks ground as first female opposition leader amid Liberal party shake-up

Health Industry Hub | May 14, 2025 |

Sussan Ley has made history as the country’s first female opposition leader, edging out former shadow treasurer Angus Taylor in […]

More


News & Trends - MedTech & Diagnostics

New procedure shows durable impact in type 2 diabetes

New procedure shows durable impact in type 2 diabetes

Health Industry Hub | May 14, 2025 |

Medtech company, Endogenex, has unveiled promising data from an Australian clinical trial that could mark a turning point in type […]

More


News & Trends - Pharmaceuticals

AI rewrites the script on androgen deprivation therapy in prostate cancer

AI rewrites the script on androgen deprivation therapy in prostate cancer

Health Industry Hub | May 14, 2025 |

Artificial intelligence is showing promise in reshaping treatment decisions for men undergoing radiation therapy and androgen deprivation therapy (ADT) for […]

More


News & Trends - MedTech & Diagnostics

MSAC to assess CGM funding for expanded access in diabetes management

MSAC to assess CGM funding for expanded access in diabetes management

Health Industry Hub | May 14, 2025 |

Applications from Abbott Australasia and Australasian Medical & Scientific Limited (AMSL) for public funding of continuous glucose monitoring (CGM) devices […]

More


This content is copyright protected. Please subscribe to gain access.